2 Dividend Stocks to Buy for a Lifetime of Passive Income
Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation maintains its dividend program, the more attractive it is to income seekers, all else being equal. However, few businesses on Wall Street can sustain consistent -- and growing -- dividends for a long time.Let's discuss two that have what it takes to pay investors regular dividends for good: Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV).Biotech giant Amgen first declared a dividend in 2011. Since then, the drugmaker has increased its payouts regularly, growing them by a whopping 750% in that period. That's a pretty good track record, and there is more where that came from, given Amgen's excellent underlying business. The company has a deep lineup of medicines that includes growth drivers like Repatha, a drug used to decrease the risk of heart attacks in certain patients; asthma therapy Tezspire; Teppezza, which treats thyroid eye disease (TED), and more.Continue reading
Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation maintains its dividend program, the more attractive it is to income seekers, all else being equal. However, few businesses on Wall Street can sustain consistent -- and growing -- dividends for a long time.
Let's discuss two that have what it takes to pay investors regular dividends for good: Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV).
Biotech giant Amgen first declared a dividend in 2011. Since then, the drugmaker has increased its payouts regularly, growing them by a whopping 750% in that period. That's a pretty good track record, and there is more where that came from, given Amgen's excellent underlying business. The company has a deep lineup of medicines that includes growth drivers like Repatha, a drug used to decrease the risk of heart attacks in certain patients; asthma therapy Tezspire; Teppezza, which treats thyroid eye disease (TED), and more.
